What is the official website of Forest Research ?

The official website of Forest Research is http://www.psypr.com.

What is Forest Research's cybersecurity risk score?

Forest Research has an AI-generated cybersecurity risk score of 755 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Forest Research experienced?

According to Rankiteo, Forest Research currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Forest Research been affected by any supply chain cyber incidents ?

According to Rankiteo, Forest Research has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Forest Research have SOC 2 Type 1 certification ?

According to Rankiteo, Forest Research is not certified under SOC 2 Type 1.

Does Forest Research have SOC 2 Type 2 certification ?

According to Rankiteo, Forest Research does not hold a SOC 2 Type 2 certification.

Does Forest Research comply with GDPR ?

According to Rankiteo, Forest Research is not listed as GDPR compliant.

Does Forest Research have PCI DSS certification ?

According to Rankiteo, Forest Research does not currently maintain PCI DSS compliance.

Does Forest Research comply with HIPAA ?

According to Rankiteo, Forest Research is not compliant with HIPAA regulations.

Does Forest Research have ISO 27001 certification ?

According to Rankiteo,Forest Research is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Forest Research operate in ?

Forest Research operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Forest Research have ?

Forest Research employs approximately 248 people worldwide.

Does Forest Research own any subsidiaries ?

Forest Research presently has no subsidiaries across any sectors.

How many LinkedIn followers does Forest Research have ?

Forest Research's official LinkedIn profile has approximately 988 followers.

What is the NAICS classification code for Forest Research ?

Forest Research is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Forest Research have a Crunchbase profile ?

No, Forest Research does not have a profile on Crunchbase.

Does Forest Research have a LinkedIn profile ?

Yes, Forest Research maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/forest-research.

How many cybersecurity incidents has Forest Research experienced ?

As of September 2, 2026, Rankiteo reports that Forest Research has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Forest Research have ?

Forest Research has an estimated 5,751 peer or competitor companies worldwide.

What types of cybersecurity incidents has Forest Research faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Vulnerability and Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Forest Research

Boost Score +25 with badge (5 left)

755

/1000

Fair

780

/1000

Fair

Forest Research Vendor Cyber Rating & Cyber Score

psypr.com

Add Your Compliance Badge

Forest has well-established franchises in the therapeutic areas of the central nervous and cardiovascular systems, and we are always exploring new product opportunities that address a range of health conditions. Our principal brands include Bystolic® (nebivolol), Daliresp™ (roflumilast), Lexapro® (escitalopram oxalate), Namenda® (memantine HCl), Savella®(milnacipran HCl), Teflaro™ (ceftaroline fosamil) for injection, and Viibryd™ (vilazodone HCl). Forest identifies, develops, and delivers pharmaceutical products that make a difference in people's lives.

Forest Research A.I CyberSecurity Scoring

Scoring History

Forest Research

Forest Research CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

AbbVie

Vulnerability

100

4/2026

EGAABB177565877...

Forest Research

Breach

100

6/2023

ABB0473723

Loading…

A.I.

Forest Research Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Forest Research

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Forest Research in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Forest Research in 2026.

Incident Types Forest Research vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Forest Research in 2026.

Incident History - Forest Research (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Forest Research Subsidiaries

Forest Research

Pharmaceutical Manufacturing

Website: http://www.psypr.com

Company Size: 5,001-10,000 employees

Forest Laboratories (now Allergan)Pharmaceutical Manufacturing

AllerganPharmaceutical Manufacturing

AbbViePharmaceutical Manufacturing

OncologyPharmaceutical Manufacturing

NeurosciencePharmaceutical Manufacturing

AbbVieEyetoEyePharmaceutical Manufacturing

ImmunologyPharmaceutical Manufacturing

AbbVie Contract ManufacturingPharmaceutical Manufacturing

VirologyPharmaceutical Manufacturing

Eye CarePharmaceutical Manufacturing

Actavis plc (now Allergan)Pharmaceutical Manufacturing

Actavis (now Allergan)Pharmaceutical Manufacturing

SkinMedica Inc., An Allergan CompanyPharmaceutical Manufacturing

India Pvt. LtdPharmaceutical Manufacturing

Loading…

Forest Research Similar Companies

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Novartis

novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Loading…

NEWS

Forest Research CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 06, 2026 08:00 AM

E&E News: Key research program stumbles at Forest Service

GREENWIRE | The Trump administration says it wants to take better care of national forests. But the first step toward meeting that goal...

Read Article

January 06, 2026 08:00 AM

E&E News: Deadly climate collision: Cutting forests and raging floods

CLIMATEWIRE | After the deadly November floods on Indonesia's Sumatra island, towns were choked with downed trees that had acted like...

Read Article

October 21, 2025 07:00 AM

Robust IoT security using isolation forest and one class SVM algorithms

The rapid growth of cloud computing and the Internet of Things (IoT) has increased the exposure of IoT devices to cyber-attacks due to their...

Read Article

October 10, 2025 07:00 AM

AI-driven cybersecurity framework for anomaly detection in power systems

The rapid evolution of smart grid infrastructure, powered by the integration of IoT and automation technologies, has simultaneously...

Read Article

September 30, 2025 07:00 AM

Save the Date: Cybersecurity Month 2025

October is National Cybersecurity Awareness Month, a nationwide campaign dedicated to increasing awareness of Internet security and...

Read Article

September 24, 2025 07:00 AM

Resilient cybersecurity in smart grid ICS communication using BLAKE3-driven dynamic key rotation and intrusion detection

The increasing convergence of Industrial Control Systems (ICS) with critical infrastructure, such as smart grids, has increased their...

Read Article

September 08, 2025 06:13 PM

Editorial: Machine learning for cybersecurity

Editorial on the Research Topic Machine learning for cybersecurity. In an era where digital transformation is reshaping every aspect of our lives,...

Read Article

August 22, 2025 07:00 AM

Article | Trump administration cuts ARPA-H funding for AI, preventive care, cybersecurity

The Trump administration is shutting down several research programs at an agency Joe Biden created to pursue high-risk, high-reward health...

Read Article

August 05, 2025 07:00 AM

E&E News: Bipartisan senators look to boost forest product research

E&E NEWS PM | A bipartisan group of senators is proposing legislation to put more of the Forest Service's research on wood products into...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-84483

SUMMARY

WWBN AVideo through commit 9c39d8c8 contains an incomplete authentication bypass in encryptPass.json.php that allows unauthenticated attackers to compute valid HMAC tokens using the public site URL and current time. Attackers can forge authentication tokens by computing hash_hmac with the site's base URL as the key and submit arbitrary passwords to receive encrypted hashes, enabling offline precomputation attacks against stolen password databases.

Published

Date2026-09-01

Updated

Date2026-09-01

RISK INFORMATION (Score: 5.3)

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-84482

SUMMARY

WWBN AVideo through commit 9c39d8c8 contains a cross-site request forgery vulnerability in the get_domain() and isSameDomain() functions that fail to properly validate referer origins. Attackers can forge requests from sibling subdomains or unparseable long-gTLD origins to perform administrative ObjectYPT writes including live server configuration changes.

Published

Date2026-09-01

Updated

Date2026-09-01

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

CVE-2026-84481

SUMMARY

WWBN AVideo through 30.0 contains an information disclosure vulnerability in the MobileManager plugin getConfiguration endpoint that returns sensitive configuration data to unauthenticated visitors. Attackers can send an unauthenticated GET request to plugin/MobileManager/getConfiguration.json.php to obtain TLS private key file paths, socket configuration details, platform version, and debug flags enabling further targeted attacks.

Published

Date2026-09-01

Updated

Date2026-09-01

RISK INFORMATION (Score: )

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-84480

SUMMARY

WWBN AVideo fails to validate password recovery token expiration in userRecoverPassSave.json.php, allowing attackers to use expired tokens to reset account passwords indefinitely. Attackers who obtain a recovery token can use it at any time to change the target account's password and gain full account access.

Published

Date2026-09-01

Updated

Date2026-09-01

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-84479

SUMMARY

WWBN AVideo (current e01e41ecc and earlier) makes three login-time security controls depend solely on the client-supplied User-Agent header. The isAVideoEncoder()/isAVideoMobileApp() checks match HTTP_USER_AGENT against a hardcoded literal ("AVideoEncoder"/"AVideoMobileApp") with no IP check or shared secret. An attacker who submits valid credentials and sets User-Agent: AVideoEncoder bypasses two-factor authentication, skips brute-force captcha escalation, and avoids being recorded in the login/device audit history. No patch is available at the time of publication.

Published

Date2026-09-01

Updated

Date2026-09-01

RISK INFORMATION (Score: 9.1)

cvss3

Base Score: 9.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…